Biopharmaceutical News and Research

RSS

Two Rutgers engineers create analytical tool to accelerate the production of biologic drugs

Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research.

18 May 2022

Landmark $20 million gift received to establish Mount Sinai-Royalty Pharma Alliance for Health Equity Research

Marking a major advance in its efforts to achieve equity in the delivery of health care, the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) announced today that its Institute for Health Equity Research (IHER) has received a landmark $20 million gift over four years from Royalty Pharma plc and certain members of its management team.

16 May 2022

New therapeutic approach for cardiac repair after a heart attack

Following a heart attack, the human body is incapable of repairing lost tissue due to the heart's inability to generate new muscle.

12 May 2022

Sphere Fluidics strengthens commercial team with three new senior hires

Key appointments form part of broader ongoing recruitment plans to support expanded operations and product development.

From Fluidic Sciences and Sphere Bio 10 May 2022

Dapagliflozin did not reduce risks in patients hospitalized with COVID-19

In a recent randomized clinical trial of hospitalized patients with COVID-19 and cardio-metabolic risk factors, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin did not significantly reduce patients' risk of organ failure, kidney problems, or death compared with placebo, although numerically fewer participants treated with dapagliflozin experienced these outcomes. The findings are published in CJASN.

29 Apr 2022

New drug shows promise in treating a movement disorder associated with Huntington's disease

A new drug has proven beneficial in treating a movement disorder commonly associated with Huntington's disease, according to a recent international study led by UTHealth Houston researcher Erin Furr Stimming, MD, who served as principal investigator on behalf of the KINECT-HD Huntington Study Group.

13 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

EMA issues qualification opinion for islet autoantibodies as enrichment biomarkers for T1D prevention trials

Critical Path Institute's Type 1 Diabetes Consortium (T1DC) today announced that the European Medicines Agency has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials.

5 Apr 2022

ProteoGenix launches new XtenCHOTM Transient CHO Expression System to improve biologics development

ProteoGenix, a contract research organization specialized in biologics discovery and bioproduction, announces the launch of its XtenCHOTM Transient Expression System.

From ProteoGenix 30 Mar 2022

The Future of Tuberculosis; An Interview with the Bill & Melinda Gates Medical Research Institute

We speak to Dr. Alemnew Dagnew from the Bill & Melinda Gates Medical Research Institute, about their tuberculosis vaccine study and the future of tuberculosis.

16 Mar 2022

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.

15 Mar 2022

The Nucleic Acid Experts – Certified Twice!

BioEcho Life Sciences receives two important hallmarks for its quality management – DIN EN ISO 9001:2015 and DIN EN ISO 13485:2016.

From BioEcho Life Sciences GmbH 10 Mar 2022

Texas A&M team continues research on the potential cure for Menkes disease

A life-saving cure solution for Menkes Disease, a copper deficiency in young children, is at the center of a licensing agreement by the The Texas A&M University System, through the Intellectual Property and Commercialization office of Texas A&M AgriLife Research, and a California-based biopharmaceutical company, Engrail Therapeutics.

3 Mar 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Single Use Support brings cell & gene therapy expert Katy Spink on board

Katherine (Katy) Spink has become a member of Single Use Support’s Board of Directors. Her many years of expertise in cell & gene therapy consulting will enrich the companies’ focus on innovating solutions for advanced therapies.

From Single Use Support GmbH 25 Feb 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022

Integrity Bio and LakePharma Become Curia

Companies Unite Under One Brand to Provide Seamless, Comprehensive Biologics Discovery, Development and Manufacturing Solutions

From Curia Global, Inc. 15 Feb 2022

NIAID's new pandemic preparedness efforts aim to characterize prototype and priority pathogens

As the global COVID-19 pandemic continues into its third year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is focusing on preparing for a range of other viral threats that could cause a public health emergency.

2 Feb 2022

Aceto consolidates acquisition of six manufacturers, strengthening its unique hybrid model that provides major supply chain benefits to customers

Aceto, a leading global provider of specialty materials for life sciences and advanced technology end markets, today reported it has consolidated and integrated its six manufacturing-related acquisitions to achieve a hybrid manufacturing/distribution model providing key benefits to its customers in high-growth end markets including pharmaceuticals, biopharmaceuticals, vaccines, nutraceuticals, agriculture, cosmetics and specialty chemicals.

27 Jan 2022

New production method developed to freeze-dry COVID-19 vaccines

UMass Lowell scientists are developing a production method to freeze-dry COVID-19 vaccines activated by messenger-RNA so they can be transported and stored at room temperature.

21 Jan 2022